Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (32)

« Back to Publications

A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-Risk Human Papillomavirus Vaccine in Women with Low-grade Cervical Lesions.

Hellner K. et al, (2025), Clin Infect Dis

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.

Kopycinski J. et al, (2023), Sci Rep, 13

Novel canonical and non-canonical viral antigens extend current targets for immunotherapy of HPV-driven cervical cancer.

Peng X. et al, (2023), iScience, 26

Novel Canonical and Non-Canonical Antigens That Extend Current Targets for Immunotherapy of HPV-Driven Cervical Cancer

Peng X. et al, (2022)

A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.

Hancock G. et al, (2019), Sci Rep, 9

MS-Rescue: A Computational Pipeline to Increase the Quality and Yield of Immunopeptidomics Experiments.

Andreatta M. et al, (2019), Proteomics, 19

Therapeutic HPV vaccines.

Hancock G. et al, (2018), Best Pract Res Clin Obstet Gynaecol, 47, 59 - 72

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.

Hancock G. et al, (2017), J Int AIDS Soc, 20

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Yang H. et al, (2016), Mol Ther, 24, 1913 - 1925

HIV-1-Related Cardiovascular Disease Is Associated With Chronic Inflammation, Frequent Pericardial Effusions, and Probable Myocardial Edema.

Ntusi N. et al, (2016), Circ Cardiovasc Imaging, 9

Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.

Hancock G. et al, (2015), PLoS Pathog, 11

Cardiac MRI demonstrates increased pericardial effusions and subclinical myocardial inflammation, as a potential cause for cardiac dysfunction in a contemporary cohort of patients with HIV

O’Dwyer E. et al, (2015), Heart, Lung and Circulation, 24, S328 - S328

Engineered Gag-specific T-cell Receptors Redirect Polyclonal CD8(+) T-cells to Clear HIV-1-infected CD4(+) T-cells from ART-treated Patients.

Yang H. et al, (2014), AIDS Res Hum Retroviruses, 30 Suppl 1

Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA.HIVconsv, in HAART-treated Subjects

Morón-López S. et al, (2014), AIDS Research and Human Retroviruses, 30, A190 - A190

HIV is an independent predictor of aortic stiffness.

Rider OJ. et al, (2014), J Cardiovasc Magn Reson, 16

Load More